Automate Your Wheel Strategy on HUMAW
With Tiblio's Option Bot, you can configure your own wheel strategy including HUMAW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HUMAW
- Rev/Share 0.0589
- Book/Share 0.2741
- PB 9.5586
- Debt/Equity 0.4398
- CurrentRatio 3.6799
- ROIC -0.7628
- MktCap 406411780.0
- FreeCF/Share -0.7664
- PFCF -4.0325
- PE -4.4359
- Debt/Assets 0.0975
- DivYield 0
- ROE 2.8597
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Humacyte, Inc. (HUMAW)
- IPO Date
- Website https://humacyte.com
- Industry Biotechnology
- CEO Dr. Laura E. Niklason M.D., Ph.D.
- Employees 218
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.